NCT00064584 2009-03-24Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)Millennium Pharmaceuticals, Inc.Phase 1 Completed60 enrolled
NCT00274248 2008-02-11MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous LeukemiaMillennium Pharmaceuticals, Inc.Phase 1 Completed